All children with inflammatory bowel disease (IBD) who were receiving maintenance infliximab at a single center between 2017 and 2018 were included in the study.
Evidence of the safety and efficacy of biosimilar infliximab CT-P13 continues to accrue, but most data on the use of the biosimilar in inflammatory bowel disease (IBD) derives from adult patients. One recent study evaluated long-term infliximab trough levels, immunogenicity, and remission rates in children with IBD who switched from the reference infliximab to biosimilar CT-P13.
All children with Crohn disease (CD) or ulcerative colitis (UC) who were receiving maintenance infliximab at a single center (which undertook a switch from reference to infliximab for all indications) between 2017 and 2018 were included in the study.
A total of 42 patients, 26 with CD and 16 with UC, were eligible for the study. They had a median duration on infliximab of 13.5 months (range, 6.8-35.5).
No significant changes in infliximab trough level occurred after the switch; the median baseline infliximab trough level was 5.7 μg/mL (range, 3.8-9.3) versus 6.5 μg/mL (range, 3.9-8.6) 6 months after the switch to the biosimilar (P = .90). The cumulative infliximab dose administered over 6 months was not significantly different before and after the switch, and 1 patient developed new antibodies to infliximab. The proportion of patients in clinical or biological remission did not significantly change, either.
No significant changes were observed in C-reactive protein, erythrocyte sedimentation rate, albumin, weight, or body mass index after the switch, and no new safety signals were observed.
Pediatric patients who receive infliximab can be successfully switched during maintenance therapy without impacting efficacy, safety, immunogenicity, or pharmacokinetics, the authors concluded.
These are welcome data that build on the limited available knowledge about using biosimilar infliximab in children with IBD. One recent review of the literature found that, in pediatric patients who started on reference or biosimilar infliximab, remission rates were similar, and no unexpected adverse events were noted.2
The review also noted similar remission rates for children who were new starts in Polish and UK studies, and reported that in Polish and Korean switching studies, respectively, disease exacerbation was not reported, and sustained remission was similar between those who switched and those who remained on reference infliximab.
Reference
1. van Hoeve K, Dreesen E, Hoffman I, Ferrante M, Ann G, Vermeire S. Swtiching from infliximab originator to a biosimilar does not affect pharmacokinetics, immunogenicity and efficacy in pediatric patients with inflammatory bowel disease. Presented at: Digestive Disease Week 2019, San Diego, California, May 18-21, 2019. Abstract 879.
2. Sieczkowska-Golub J, Jarzebicka D, Oracz G, Kierkus J. Biosimilars in paediatric inflammatory bowel disease. World J Gastroenterol. 2018;24(35):4021-4027. doi: 10.3748/wjg.v24.i35.4021.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.